Correspondence  by unknown
years of experience, I have learned two alarming facts. First,
conversations with jurors after a trial reveal that jurors accept
the testimony of professional witness without prejudice. The
fact that a physician makes a living testifying against other
physicians does not seem to disturb them. Second, the tech-
nicalities involved in many malpractice cases are light-years
outside the competence of the average jury: Lawyers and
professional witnesses are quick to take advantage of this fact.
Major legal reforms are urgent. The following steps are
logical and feasible: 1) The jury system should be excluded
in a professional liability hearing; 2) A judge should reach a
final verdict on the basis of expert testimony provided by
members of a panel of disinterested, objective, acknowledged
experts. A permanent panel of such experts should be main-
tained and the expert testimony should be provided gratis: At
most, the witness should be reimbursed for out-of-pocket
expenses. (The various specialty colleges could easily compile
such lists.); 3) The British system of loser-pays-all should be
adopted; and 4) The British system of absolutely excluding
testimony by a paid witness should be adopted.
Obviously, this solution will take time. In the interim, a
practicable palliative measure lies ready at hand. I urge my
colleagues to offer their services as I do, as an unpaid, impartial
expert, ready to review any case in my respective disciplines: If
they explain to the legal fraternity that they do this pro bono,
this simple measure will have a substantial influence.
As a first step, the several specialty colleges could compile
lists of volunteer impartial expert witnesses and provide
defendants with names in any given geographic locale when
a suit is filed. I find that a number of colleagues around the
country are doing exactly what I do, and we agree that the
work is not particularly onerous because it is possible to
review any hospital record and reach conclusions in about 30
minutes.
The malpractice crisis can be overcome by simple, fair-
minded measures. It is time for the several organized
specialty groups and organized medicine in general to take
appropriate steps.
Brendan P. Phibbs, MD
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The Influence of Age and
Gender On Heart Rate Variability (HRV)
The recent article of Umetani et al. (1) on the relation of
time domain heart rate variability (HRV) and heart rate
(HR) to age and gender presented much important infor-
mation. Nevertheless, there are serious inconsistencies in
their methodology and not all conclusions are substantiated
by their results. Although the authors acknowledge that it is
recognized that a (logarithmic) tranformation is necessary to
achieve a normal distribution of certain HRV indices, it is
not clear which tranformation, if any, was performed before
tests that require normally distributed variables, such as
Student t test or ANOVA, were used. A normal distribu-
tion, tested by e.g., the one sample Kolmogorov-Smirnov
test, can be obtained by a natural logarithmic transformation
for rMSSD and by calculating the square root for pNN50
(2). Furthermore, all age groups above 60 are substantially
underrepresented (e.g., only six men in the age category
80–99). Therefore, statements as “HRV . . . exhibits an
accelerated decline the . . . ninth and tenth decades” should
be interpreted with caution. Statistical analysis on a two-
decade basis to ensure an “adequate number” of subjects in
each group is an artifice that is not warranted because first,
a rapid evolution in autonomic modulation between the ages
of 10 and 30 can be expected, and second, the disappearance
of the gender difference is situated in the decade beyond age
40 (2), and not, as stated by the authors, between 50 and 69.
The authors report that the correlations of SD and
SDANN with age were lower than those of SDNN index,
rMSSD and pNN50. However, they fail to mention that
this can be attributed solely to an absence of any correlation
for SD and SDANN with age in female subjects. In Figure
3, correlation coefficients of r 5 –0.24 and –0.20 are
presented for women, which can be disregarded, because in
biomedical sciences, they indicate only little or no relation-
ship (3).
We disagree with the statement that the gender differ-
ences they observed could reflect lower levels of parasym-
pathetic activity in “young” female subjects and that this
view is supported by a higher HR in female subjects. This
may be true for teenagers, but not for adults (2). In their
two-decade age group 30–49 HR is still significantly higher
in women, and no significant difference in vagal indices is
detected. The suggestion that this may be related to a higher
level of sympathetic activity is not substantiated by the
results. SDNN index has not been accepted as a substitute
for heart rate spectral analysis (HRSA) low-frequency
power (4), the only available parameter that reflects pre-
dominantly sympathetic modulation (5) in physiological
conditions. HRSA was not performed in this study. The
higher HR in female patients can also be related to their
lower stroke volume. Furthermore, the reported gender
differences may derive from different central autonomic and
neurohumoral mechanisms in male and female patients
rather than solely from differences in autonomic outflow or
modulation.
No correction was made in the statistical analysis for
mean HR, a major determinant of HRV (6), and day/night
changes, that markedly affect autonomic modulation, were
not taken into account.
The reported results (1) complete previous reports on the
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effect of age and gender on time-domain HRV and HR, at
least in the young and middle-aged. If the authors had
included a sufficient number of participants (at least 20
healthy subjects per decade and per gender), this article
indeed could have delineated the effects of age and gender
on time-domain HRV and would have forwarded normal
ranges of HRV and HR over nine decades. Unfortunately,
only their most important study limitation can be empha-
sized: Additional larger studies that include the underrep-
resented groups are needed.
Dirk Ramaekers, MD
Hugo Ector, MD, PhD
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REPLY
We appreciate the interest of Drs. Ramaekers, Ector, and
Aubert in our recent report on age and gender effects on
heart rate variability (HRV) and heart rate (HR) (1) and
have reexamined our data with respect to the questions
posed. Unfortunately, the authors did not provide a sum-
mary of their own data (2), on which they seem to largely
base their comments. This detracts from meaningful com-
parisons with their data.
Insofar as the questions posed are concerned, please
consider the following. A number of the issues also are
discussed in the limitations section of the article.
1. Raemakers et al. stated that statistical analysis should
have been preceded by a log transformation. We agree
that a transformation should be carried out in instances
where data are skewed. However, we compared limited
10 year age-range groups and found that data for 6 of the
8 age groups were normally distributed, even using the
pNN50 measure. Therefore, we felt justified in not
subjecting the data to log transformation before analysis.
2. We agree that the relatively small number of subjects in
the oldest age groups, particularly men over age 70,
represents a limitation of the study and that caution is
indicated in interpreting the decrease in HRV in this
group of subjects. However, to our best knowledge, this
is the largest published HRV data set to date for healthy
individuals over age 70. We are currently collecting data
from additional subjects over age 70, but it may be
difficult to achieve equal numbers of healthy older men
and women due to gender differences in mortality.
3. We agree with Raemakers et al. that a larger sample size
would be helpful in delineating the physiologic mecha-
nisms underlying age related gender HRV differences
and state this in our article. Larger sample size also
would permit a decade-by-decade analysis. Suggestions
that power spectrum analysis may be important with
respect to mechanistic determinations would be more
relevant if power spectral bands associated with sympa-
thetic activity were well defined.
More specifically, in our study, gender effects on HRV
were measure dependent. As shown in scatter plots of
HRV data from our total sample (Figure 2 B and C) (1)
HRV determined using rMSSD and pNN50 decreases
markedly with aging before age 50. Using these mea-
sures, HRV of young women is lower than that of age
matched men, with gender differences disappearing after
age 30. Parasympathetic modulation of heart rate (HR)
also decreases with aging (to age 30) (3). Using SDNN,
SDANN, and SDNN index measures, gender differences
disappear after age 50. Findings that HRV of women
determined using pNN50 and rMSSD, which reflect
parasympathetic activity, is lower than in age matched
men, suggest that gender HRV differences, at least
before age 30, may reflect differences in parasympathetic
modulation.
4. We agree that the lesser age dependence of SDNN and
SDANN measures may be largely due to the lesser age
dependence of SDNN and SDANN in females.
5. As mentioned by Ramaekers et al. (2) and others (4), HR
is a major determinant of HRV. Circadian changes also
represent an important consideration. However, in this
report, we did not consider these because it would have
made the report too long and complex. In addition, to
our best understanding, there are no established methods
for correcting HRV for mean HR. Tsuji et al. (4)
reported aging and HR effects on HRV separately.
In conclusion, we again thank Dr. Ramaekers and his
colleagues for their comments. However, we believe that
despite the limitations, our study has important implications
to our understanding HRV of normal individuals over the
life span and to the predictive use of HRV with respect to
mortality and cardiovascular morbidity, particularly in older
individuals.
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